When was Solarea Bio founded?

Solarea Bio was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Solarea Bio located?

Solarea Bio is headquartered in Cambridge, United States.

Who is the current CEO of Solarea Bio?

Gerardo V Toledo of Solarea Bio. They have also founded 1 company.

How many employees does Solarea Bio have?

As of Sep 30, 2026, the latest employee count at Solarea Bio is 16.

Is Solarea Bio a funded company?

Solarea Bio is a funded company, having raised a total of $37.2M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 26, 2017.

When was the latest funding round of Solarea Bio?

Solarea Bio's latest funding was a $***** Series B round on Nov 04, 2025, with participation from 0 investor.

Where does Solarea Bio rank among its competitors?

Solarea Bio ranks 355th amongst 3130 active competitors, of which 1067 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Solarea Bio?

Solarea Bio's top competitors include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Solarea Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Innovating microbial solutions for human health, focusing on aging well. The company rapidly innovates and delivers breakthrough solutions for unmet medical needs, particularly in aging health. They are committed to advancing health outcomes through microbial science. Their core values include integrity, scientific rigor, diversity and inclusion, tenacity, a sense of purpose, transparency, and innovation. They develop products to address dietary needs related to rheumatoid arthritis, psoriatic arthritis, and cellular aging. The company uses a rigorous process involving discovery, development, preclinical testing, and clinical trials. They aim to provide trustworthy solutions for health conditions, incorporating the highest level of scientific rigor into every aspect of their process. They are dedicated to improving collective health outcomes and providing transparent formulations.

Website: solareabio.com
Email ID: *****@solareabio.com

Key Metrics

Founded Year

2017

Location

Cambridge, United States

Stage

Series B

Total Funding

$37.2M in 5 rounds

Latest Funding Round

Series B, Nov 04, 2025, $*****

Investors

S2G Investments & 9 more

Ranked

355^th among 3130 active competitors

Employee Count

16 as on Sep 30, 2026

Similar Companies

Alnylam & 988 more

View Solarea Bio's full profile

Solarea Bio has raised a total funding of $37.2M over 5 rounds. Its first funding round was on Jul 26, 2017. Solarea Bio has 10 institutional investors.

Here is the list of recent funding rounds of Solarea Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 04, 2025	4273585	Series B	7379984	1365593	4696677	6431167
Aug 27, 2024	8333606	Series B	6785436	1905901	1451086	5479445
May 08, 2023	5308843	Series B	7308348	9553603	S2G Investments	Bold Capital Partners & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Solarea Bio's funding rounds and investors

The founders of Solarea Bio is Gerardo V Toledo. Gerardo V Toledo is the CEO of Solarea Bio.

Here are the details of Solarea Bio's key team members:

Gerardo V Toledo: Co-Founder & CEO of Solarea Bio.
Contact Info: 1 email address

View details of Solarea Bio's Founder profiles and Board Members

Solarea Bio's employee count trend

Solarea Bio has 16 employees as of Sep 26. Here is Solarea Bio's employee count trend over the years:

Uncover Solarea Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Solarea Bio include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of Solarea Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
355th	Solarea Bio 2017, Cambridge (United States), Series B	Innovating microbial solutions for human health, focusing on aging well	$37.2M	Rising Tide Fund, Bold Capital Partners & 8 others	51/100